ICS II decreased levels of Aβ1-40 and Aβ1-42 and inhibited inflammatory factors, including IL-1β, TNF-α, cyclooxygenase (COX)-2, and TGF-β1, in AD. The gene discussed is TGFB1; the disease is Alzheimer disease.